Diabetes 54:78-84, 2005
© 2005 by the American Diabetes Association, Inc.
Treatment With Granulocyte ColonyStimulating Factor Prevents Diabetes in NOD Mice by Recruiting Plasmacytoid Dendritic Cells and Functional CD4+CD25+ Regulatory T-Cells
Hassen Kared1,
Annie Masson1,
Homa Adle-Biassette2,
Jean-François Bach1,
Lucienne Chatenoud1, and
Flora Zavala1
1 National Institute of Health and Medical Research, INSERM U580, Necker Enfants Malades Research Institute, Hôpital Necker, Paris, France
2 Pathology Laboratory, Bichat-Claude Bernard Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
Accumulating evidence that granulocyte colonystimulating factor (G-CSF), the key hematopoietic growth factor of the myeloid lineage, not only represents a major component of the endogenous response to infections, but also affects adaptive immune responses, prompted us to investigate the therapeutic potential of G-CSF in autoimmune type 1 diabetes. Treatment with G-CSF protected NOD mice from developing spontaneous diabetes. G-CSF triggered marked recruitment of dendritic cells (DCs), particularly immature CD11cloB220+ plasmacytoid DCs, with reduced costimulatory signal expression and higher interferon- but lower interleukin-12p70 release capacity than DCs in excipient-treated mice. G-CSF recipients further displayed accumulation of functional CD4+CD25+ regulatory T-cells that produce transforming growth factor-ß1 (TGF-ß1) and actively suppressed diabetes transfer by diabetogenic effector cells in secondary NOD-SCID recipients. G-CSFs ability to promote key tolerogenic interactions between DCs and regulatory T-cells was demonstrated by enhanced recruitment of TGF-ß1expressing CD4+CD25+ cells after adoptive transfer of DCs isolated from G-CSF relative to vehicle-treated mice into naive NOD recipients. The present results suggest that G-CSF, a promoter of tolerogenic DCs, may be evaluated for the treatment of human type 1 diabetes, possibly in association with direct inhibitors of T-cell activation. They also provide a rationale for a protective role of the endogenous G-CSF produced during infections in early diabetes.
Address correspondence and reprint requests to Flora Zavala, DSc, INSERM U580, Necker Institute, 161 rue de Sèvres, 75743 Paris Cedex 15, France. E-mail: zavala{at}necker.fr

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Huang, I. J. Fugier-Vivier, T. Miller, M. J. Elliott, H. Xu, L. D. Bozulic, P. M. Chilton, and S. T. Ildstad
Plasmacytoid Precursor Dendritic Cells From NOD Mice Exhibit Impaired Function: Are They a Component of Diabetes Pathogenesis?
Diabetes,
September 1, 2008;
57(9):
2360 - 2370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gaudreau, C. Guindi, M. Menard, G. Besin, G. Dupuis, and A. Amrani
Granulocyte-Macrophage Colony-Stimulating Factor Prevents Diabetes Development in NOD Mice by Inducing Tolerogenic Dendritic Cells that Sustain the Suppressive Function of CD4+CD25+ Regulatory T Cells
J. Immunol.,
September 15, 2007;
179(6):
3638 - 3647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. E. Raveney and D. J. Morgan
Dynamic Control of Self-Specific CD8+ T Cell Responses via a Combination of Signals Mediated by Dendritic Cells
J. Immunol.,
September 1, 2007;
179(5):
2870 - 2879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Bharadwaj, M. Li, R. Zhang, C. Chen, and Q. Yao
Elevated Interleukin-6 and G-CSF in Human Pancreatic Cancer Cell Conditioned Medium Suppress Dendritic Cell Differentiation and Activation
Cancer Res.,
June 1, 2007;
67(11):
5479 - 5488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Brode, T. Raine, P. Zaccone, and A. Cooke
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
J. Immunol.,
November 15, 2006;
177(10):
6603 - 6612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rutella, S. Danese, and G. Leone
Tolerogenic dendritic cells: cytokine modulation comes of age
Blood,
September 1, 2006;
108(5):
1435 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Condomines, P. Quittet, Z.-Y. Lu, L. Nadal, P. Latry, E. Lopez, M. Baudard, G. Requirand, C. Duperray, J.-F. Schved, et al.
Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor.
J. Immunol.,
June 1, 2006;
176(11):
6631 - 6639.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Morris, K. P. A. MacDonald, and G. R. Hill
Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
Blood,
May 1, 2006;
107(9):
3430 - 3435.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Teuscher, R. W. Doerge, P. D. Fillmore, and E. P. Blankenhorn
eae36, a Locus on Mouse Chromosome 4, Controls Susceptibility to Experimental Allergic Encephalomyelitis in Older Mice and Mice Immunized in the Winter
Genetics,
February 1, 2006;
172(2):
1147 - 1153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Rutella, F. Zavala, S. Danese, H. Kared, and G. Leone
Granulocyte Colony-Stimulating Factor: A Novel Mediator of T Cell Tolerance
J. Immunol.,
December 1, 2005;
175(11):
7085 - 7091.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Diabetes Association.
|
|
| |
|